29.07.2024
RELATOX: New indications for the use in Uzbekistan
14.06.2024
Microgen's preparation for chronic migraines has been approved by the Ministry of Health in Kyrgyzstan
23.05.2024
Botulinum toxin of SPA ‘Microgen’ to treat arm muscle spasticity in patients with neurological diseases
25.10.2023
Nacimbio brings to market new Hepatitis B drug
04.06.2021
New productions to be created at Microgen
01.06.2021
Relatox® entered the Uzbek market
20.05.2021
Microgen increases the export of pharmaceuticals to Uzbekistan
26.04.2021
NPO Microgen and National Association of the Specialists in Infections Control agreed to pool efforts in vaccination popularization area
15.04.2021
Perm subsidiary of NPO Microgen to expand the production of vaccines and blood products
09.02.2021
Microgen obtained registration for the new vaccine
23.12.2020
Microgen launched a mobile application about vaccines
07.12.2020
Relatox won the prestigious Beauty Award ′′Crystal Lotus”
02.12.2020
Evgeny Stavnichy was appointed Director of NPO Microgen Ufa subsidiary.
06.08.2020
Microgen to start the production of new allergy drugs
20.07.2020
Microgen started shipping its “three in one” combined vaccine against measles, rubella and mumps
28.05.2020
Perm subsidiary of NPO Microgen finished modernization of vaccine production department
25.03.2020
Bacteriophage products were included into the European Position Paper on Rhinosinusitis and Nasal Polyps treatment
27.02.2020
Bacteriophage products have been included into clinical recommendations for urology
06.02.2020
Microgen opened Biological Resource Center for bacteriophages study
29.01.2020
Relatox in dentistry: options of use